← Leaderboards
Kanneboyina Nagaraju
Children'S Research Institute
$4,117,501
Attributed
$4,312,501
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $570.1K · FY2005–18$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$4,312,501 · 7
By mechanism
R01$1,924,727 · 1
U54$749,765 · 1
K26$526,039 · 2
R21$437,064 · 1
R56$390,000 · 1
P50$284,906 · 1
Top collaborators
- Terence A Partridge1 shared
Most similar at Children'S Research Institute
Same institution · by research overlap
- Travis Kinder$128,028
- Terence A Partridge$2,629,382
- Susan Sparks$285,628
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseMouse ModelMolecularMediatingIn VivoMuscle FibersCellsMusclePharmaceutical PreparationsDystrophinTissuesProteinsMyositisDrug EfficacyPathogenesisPhenotypeInbred Mdx MiceChronicBiochemicalFunctional DisorderChildClinical TrialsMedical CenterMonitor
Grant awards (22)
Virus induced genetic changes in the pathogenesis of autoimmune myositis$237,390
R21 · FY2018 · AI · contact PI
Virus induced genetic changes in the pathogenesis of autoimmune myositis$199,674
R21 · FY2017 · AI · contact PI
Dystrophin turnover after exon-skipping$390,000
R56 · FY2016 · NS · contact PI
Preclinical dosing optimization: Dosing schedule, tissue$146,474
U54 · FY2015 · HD · contact PI
Preclinical drug trial in mouse models of inflammation$78,300
K26 · FY2015 · OD · contact PI
Preclinical drug trial in mouse models of inflammation$27,949
K26 · FY2015 · OD · contact PI
Preclinical dosing optimization: Dosing schedule, tissue$141,786
U54 · FY2014 · HD · contact PI
Preclinical drug trial in mouse models of inflammation$106,249
K26 · FY2014 · OD · contact PI
Preclinical dosing optimization: Dosing schedule, tissue$137,866
U54 · FY2013 · HD · contact PI
Preclinical drug trial in mouse models of inflammation$101,043
K26 · FY2013 · OD · contact PI
Preclinical dosing optimization: Dosing schedule, tissue$144,695
U54 · FY2012 · HD · contact PI
Preclinical drug trial in mouse models of inflammation$106,249
K26 · FY2012 · OD · contact PI
In vitro and in vivo functional assays$284,906
P50 · FY2011 · AR · contact PI
Preclinical dosing optimization: Dosing schedule, tissue$178,944
U54 · FY2011 · HD · contact PI
Preclinical drug trial in mouse models of inflammation$106,249
K26 · FY2011 · RR · contact PI
Pathogenesis of autoimmune myositis: Role of MHC Class 1$339,350
R01 · FY2009 · AR · contact PI
Pathogenesis of autoimmune myositis: Role of MHC Class 1$224,338
R01 · FY2009 · AR · contact PI
Pathogenesis of autoimmune myositis: Role of MHC Class 1$339,350
R01 · FY2008 · AR · contact PI
Pathogenesis of autoimmune myositis: Role of MHC Class 1$346,276
R01 · FY2007 · AR · contact PI
Pathogenesis of autoimmune myositis: Role of MHC Class 1$356,618
R01 · FY2006 · AR · contact PI
Pathogenesis of autoimmune myositis: Role of MHC Class 1$218,951
R01 · FY2005 · AR
Pathogenesis of autoimmune myositis: Role of MHC Class 1$99,844
R01 · FY2005 · AR